Evaluating a new dengue vaccine in healthy participants.
Official title: A STUDY TO ASSESS EFFICACY, SAFTETY AND PHARMACOKINETICS OF EYU688 IN HEALTHY PARTICIPANTS CHALLENGED WITH DENGUE SEROTYPE 2
Funded at Johns Hopkins University · NIH-10925568 · Data updated 2026-11-12
This study is looking for healthy people to try out a new dengue vaccine called EYU688 to see how well it works and if it’s safe, as they will be exposed to the dengue virus; by joining, you'll help in the effort to create a vaccine that could protect against dengue fever.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 23, 2023 |
| Project end | July 22, 2025 |
| Funding year | 2023 |
| Award (this year) | $3,096,871 |
| NIH project number | 75N93019D00031-0-759302300004-1 |
| Project ID | NIH-10925568 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are healthy adults who are willing to participate in a clinical trial and are at risk of dengue virus exposure.
✕Less likely to help
Patients with pre-existing health conditions or those who have previously been infected with dengue may not benefit from this research.
What this research studies
This research investigates the safety and effectiveness of a new dengue vaccine candidate called EYU688 in healthy individuals who are intentionally exposed to Dengue virus serotype 2. Participants will receive the vaccine and then be monitored for their immune response and any side effects. The study aims to gather important data on how well the vaccine works and how it is processed in the body. By participating, individuals will contribute to the development of a potential vaccine that could protect against dengue fever.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective vaccine for dengue fever, potentially reducing the incidence of this viral disease.
How similar studies have gone: Previous research on dengue vaccines has shown promise, indicating that this approach could lead to significant advancements in dengue prevention.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Durbin, Anna Palmer — Johns Hopkins University
- Study coordinator: Durbin, Anna Palmer
Related research
Other NIH-funded projects on the same topics.
-
Sub-second acetylcholine release in the brain for Alzheimer’s dementia
A small, quick stimulations-based study aims to boost a brain chemical called acetylcholine to help people with Alzheimer’s disease by using a targeted brain stimulation approach.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.